Cingulate Inc (CING) Stock Price, Quote & News

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1...

Industry: Biotechnology

Sector: Healthcare

Phone: 913 942 2300

Website: www.cingulate.com

Address:

1901 West 47th Place, Kansas City, United States

FatherofTrades Mar. 1 at 7:33 PM

Current high conviction longs: $SLS $CING $TEAD $ANNA $RILY

0 · Reply

Fluxorfg Mar. 1 at 7:20 PM

$CING biotech microcap coiling watching for breakout

0 · Reply

Itinerant Mar. 1 at 6:56 PM

$CING I find it strange that the company is trading at a market cap of about $55 million under the facts....imminent PDUFA, superior product, and very large market. The negatives include numerous products in competition and the usual challenges of product launch. I stay long, but I expect a sell the news event on approval. JMO

0 · Reply

BioTechHealthX Mar. 1 at 3:32 PM

$CING Cingulate (NASDAQ: CING) closed a $12 million PIPE financing at-the-market, signaling institutional confidence ahead of its planned CTx-1301 launch. With strong investor alignment, insider participation, and a growing ADHD treatment opportunity, is this small-cap biotech ready for a major move? https://biotechhealthx.com/biotech-news/is-it-time-to-take-profit-in-cingulate-cing/

0 · Reply

BioTechHealthX Mar. 1 at 3:15 PM

$ADAP $ARVN $CING $CRVS $ETON A single FDA approval can double a small-cap biotech stock overnight. Discover 10 high-risk, high-reward FDA catalyst stocks with confirmed PDUFA dates this quarter that traders are watching for breakout moves, volatility spikes, and potential buyout speculation. https://biotechhealthx.com/biotech-news/top-10-small-cap-fda-catalyst-biotech-stocks/

0 · Reply

signaljumper Mar. 1 at 3:07 PM

$CING Cingulate Inc NEW: Free Sunday stock report is out now. https://www.patreon.com/posts/stock-report-inc-151956780?utm_medium=social&utm_source=twitter&utm_campaign=postshare_creator&utm_content=join_link

0 · Reply

buymoremakemore Mar. 1 at 4:56 AM

$CING safety and efficacy shouldnt be a concern here since this stimulant chemistry has been around a while. More cmc. Therefore this might have a nice PDUFA runup.

1 · Reply

fullobullz Mar. 1 at 12:23 AM

$CING So are we looking at sell off on monday and rebound on tues? I'll be surprised if this iran thing goes till Friday.

1 · Reply

TheSuper Feb. 28 at 2:48 PM

$CING Tell me you have done 0 DD without saying you have done 0 DD.

0 · Reply

SaTwits Feb. 28 at 1:57 AM

$CING feels like the good news might be baked in

2 · Reply

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Oct 23, 2025, 4:45 PM EDT - 4 months ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Sep 17, 2025, 8:45 AM EDT - 5 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Aug 21, 2025, 4:35 PM EDT - 6 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 19, 2025, 8:45 AM EDT - 6 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 15, 2025, 9:00 AM EDT - 7 months ago

Cingulate Provides Management Team Update

Aug 6, 2025, 8:45 AM EDT - 7 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Jun 18, 2025, 8:00 AM EDT - 9 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

May 8, 2025, 4:30 PM EDT - 10 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Apr 9, 2025, 8:00 AM EDT - 11 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Dec 23, 2024, 7:30 AM EST - 1 year ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 16, 2024, 5:00 PM EDT - 2 years ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Mar 6, 2024, 6:45 AM EST - 2 years ago

Cingulate to Attend DCAT Week 2024 in New York City

Feb 13, 2024, 6:45 AM EST - 2 years ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 6, 2024, 4:15 PM EST - 2 years ago

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 2 years ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Jan 29, 2024, 8:00 AM EST - 2 years ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 6:45 AM EST - 2 years ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

May 25, 2023, 3:55 PM EDT - 3 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

FatherofTrades Mar. 1 at 7:33 PM

Current high conviction longs: $SLS $CING $TEAD $ANNA $RILY

0 · Reply

Fluxorfg Mar. 1 at 7:20 PM

$CING biotech microcap coiling watching for breakout

0 · Reply

Itinerant Mar. 1 at 6:56 PM

0 · Reply

BioTechHealthX Mar. 1 at 3:32 PM

0 · Reply

BioTechHealthX Mar. 1 at 3:15 PM

0 · Reply

signaljumper Mar. 1 at 3:07 PM

0 · Reply

buymoremakemore Mar. 1 at 4:56 AM

$CING safety and efficacy shouldnt be a concern here since this stimulant chemistry has been around a while. More cmc. Therefore this might have a nice PDUFA runup.

1 · Reply

fullobullz Mar. 1 at 12:23 AM

$CING So are we looking at sell off on monday and rebound on tues? I'll be surprised if this iran thing goes till Friday.

1 · Reply

TheSuper Feb. 28 at 2:48 PM

$CING Tell me you have done 0 DD without saying you have done 0 DD.

0 · Reply

SaTwits Feb. 28 at 1:57 AM

$CING feels like the good news might be baked in

2 · Reply

BillionerOfKing Feb. 28 at 1:18 AM

$CING Current Stock Price: $6.27

0 · Reply

wanderlust222 Feb. 27 at 9:07 PM

$CING 2,000 more for moi

1 · Reply

Achouffe Feb. 27 at 2:52 PM

$CING Double at $6,4

0 · Reply

HeekLikeThis Feb. 26 at 9:02 PM

$CING It would be best for us to trade in the $7–8 range until a few days before the approval. Then we get news about the patent and the FDA approval. Those two pieces of news, released within a few days of each other, could drive the price up to $60–70🍀💚

0 · Reply

Juhanialainen Feb. 26 at 8:17 PM

Next month will be extraordinary for my ”biotech ETF”: $SLS, $OSTX, $CING and $IBRX. Even more than this month. Thank you for your attention for this matter.

3 · Reply

stockchacing Feb. 26 at 5:44 PM

$CING Although some are speculating that this video could even mention $SLS at a point ( after 7min40), it makes me very optimistic about the PDUFA approval which is scheduled for May 31st. So, actually, we only need to wait 3 more months before we can start selling the drug... AND WE ARE STILL BELOW 7 $ SHAREPRICE ???!!!???? OMG, what an opportunity we have here... I am expecting $80+ SP after approval. Gotta buy more!!!!!!! NFA just my own opinion. https://www.bing.com/videos/riverview/relatedvideo?q=marty+makary+fda+today&&mid=113FD2379AAC1C212EB8113FD2379AAC1C212EB8&churl=&FORM=VRDGAR

3 · Reply